127 related articles for article (PubMed ID: 3839284)
21. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
23. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
24. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
[TBL] [Abstract][Full Text] [Related]
25. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
Hornedo J; Van Echo DA
Pharmacotherapy; 1985; 5(2):78-90. PubMed ID: 2582401
[TBL] [Abstract][Full Text] [Related]
26. AMSA--a promising new agent in refractory acute leukemia.
Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
[TBL] [Abstract][Full Text] [Related]
27. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
[TBL] [Abstract][Full Text] [Related]
28. [Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
Marit G; David B; Reiffers J; Broustet A
Bull Cancer; 1985; 72(1):37-41. PubMed ID: 3857082
[TBL] [Abstract][Full Text] [Related]
29. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
Arlin ZA; Ahmed T; Mittelman A; Feldman E; Mehta R; Weinstein P; Rieber E; Sullivan P; Baskind P
J Clin Oncol; 1987 Mar; 5(3):371-5. PubMed ID: 3546613
[TBL] [Abstract][Full Text] [Related]
30. [Experiences with HD-Ara C treatment in leukemia patients].
Jehn U
Onkologie; 1985 Feb; 8(1):37-8. PubMed ID: 3885118
[TBL] [Abstract][Full Text] [Related]
31. Amsacrine [4'-(9-acridinylamino)-methanesulfon-m-anisidide] (m-AMSA) and 5-azacytidine (AZA) for remission reinduction in patients with relapsed adult acute nonlymphocytic leukemia. An ECOG pilot study. Eastern Cooperative Oncology Group.
Kahn SB; Spiers A; Knospe WH; Soojian M; Glick JH
Am J Clin Oncol; 1987 Feb; 10(1):78-81. PubMed ID: 2435142
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
33. Early intensification of chemotherapy for childhood acute nonlymphoblastic leukemia: improved remission induction with a five-drug regimen including etoposide.
Kalwinsky D; Mirro J; Schell M; Behm F; Mason C; Dahl GV
J Clin Oncol; 1988 Jul; 6(7):1134-43. PubMed ID: 3292713
[TBL] [Abstract][Full Text] [Related]
34. Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
Miller LP; Pyesmany AF; Wolff LJ; Rogers PC; Siegel SE; Wells RJ; Buckley JD; Hammond GD
Cancer; 1991 May; 67(9):2235-40. PubMed ID: 1707336
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia: a Pediatric Oncology Group study.
Sadowitz PD; Dubowy R; Souid A; Pollock BH; Weinstein H; Parmley RT; Bowman WP; Land V; Vats T; Pratt C
J Clin Oncol; 1994 Sep; 12(9):1969-73. PubMed ID: 8083718
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
[TBL] [Abstract][Full Text] [Related]
37. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Steuber CP; Krischer J; Holbrook T; Camitta B; Land V; Sexauer C; Mahoney D; Weinstein H
J Clin Oncol; 1996 May; 14(5):1521-5. PubMed ID: 8622066
[TBL] [Abstract][Full Text] [Related]
38. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
Zittoun R; Rio B; Marie JP; Blanc CM
Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
[TBL] [Abstract][Full Text] [Related]
39. A phase I and II study of m-AMSA in acute leukaemia.
Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
[TBL] [Abstract][Full Text] [Related]
40. Amsacrine with high-dose cytarabine in acute leukemia.
Zittoun R; Bury J; Stryckmans P; Lowenberg B; Peetermans M; Rozendaal KY; Haanen C; Kerkhofs M; Jehn U; Willemze R
Cancer Treat Rep; 1985 Dec; 69(12):1447-8. PubMed ID: 3841026
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
